Condition: Nasopharyngeal Carcinoma · Sponsor: Zhejiang Cancer Hospital
Radiotherapy combined with recombinant human endostatin and capecitabine for patients with nasopharyngeal carcinoma (NPC) resistant to induction chemotherapy.
This description comes directly from the study's public registry record.
Ting Jin, MD · +86-571-88128202 · jinting@zjcc.org.cn
Always discuss trial participation with your own doctor first.
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
| the First Hospital of Jiaxing | Jiaxing, Zhejiang, China | Recruiting |
| Jinhua Central Hospital | Jinhua, Zhejiang, China | Recruiting |
| The Central Hospital of Lishui City | Lishui, Zhejiang, China | Recruiting |
| Ningbo First Hospital | Ningbo, Zhejiang, China | Recruiting |
| Ningbo Medical Center Lihuili Eastern Hospital | Ningbo, Zhejiang, China | Recruiting |
| People's Hospital of Quzhou | Quzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05514275